Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study
American Journal of Health-System Pharmacy · 2024
DOI: 10.1093/ajhp/zxae053 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Munaza Riaz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Valsartan, Aminobutyrates, Heart Failure, Biphenyl Compounds. Die Arbeit nennt 27 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Purpose
Sacubitril/valsartan (SAC/VAL) or angiotensin receptor blockers (ARBs) are recommended therapy for heart failure with preserved ejection fraction (HFpEF), but little is known about their real-world comparative effectiveness among patients with HFpEF. The objective of this study was to determine the comparative effectiveness of SAC/VAL vs ARBs in preventing HF-related hospitalization or all-cause hospitalization among patients with HFpEF.
Methods
We conducted a cohort study using IBM MarketScan commercial and Medicare supplemental databases to identify patients aged 18 years or older with a diagnosis of HFpEF and initiation of SAC/VAL (2015-2020) or ARB (2009-2014) therapy. The index date was the date of the first SAC/VAL or ARB prescription fill. After propensity score (PS) matching with a ratio of 1 up to 3, Cox proportional hazards regression was used with robust variance estimators to compare the risks of HF-related hospitalization and all-cause hospitalization between the 2 therapies. Several subgroup and sensitivity analyses were conducted to check the robustness of the main analysis.
Results
After PS matching, 2,520 patients (846 receiving SAC/VAL and 1,674 receiving an ARB) were included in the final analyses. After controlling for covariates, there was no difference in the risk of HF-related hospitalization between SAC/VAL and ARB recipients (adjusted hazard ratio [aHR], 1.33; 95% confidence interval [CI], 0.99-1.77). There was also no difference in the risk of all-cause hospitalization between SAC/VAL and ARB recipients (aHR, 1.06; 95% CI, 0.91-1.24).
Conclusion
Among individuals with private or Medicare Advantage insurance plans, there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between adults with HFpEF who received SAC/VAL and those who received ARB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA.
- Lahore College for Women University, Lahore, Pakistan.
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL.
- Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
ORCID-Profile: Haesuk Park
Zitieren
APA
Riaz, M., Smith, S. M., Dietrich, E. A., Winchester, D. E., Guo, J., & Park, H. (2024). Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae053
Vancouver
Riaz M, Smith SM, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae053
BibTeX
@article{Riaz2024,
author = {Riaz, Munaza and Smith, Steven M and Dietrich, Eric A and Winchester, David E and Guo, Jingchuan and Park, Haesuk},
title = {Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study},
journal = {American Journal of Health-System Pharmacy},
year = {2024},
doi = {10.1093/ajhp/zxae053}
}
EUVIMED